TY - JOUR
T1 - Development of diagnostic prediction tools for bacteraemia caused by third-generation cephalosporin-resistant enterobacteria in suspected bacterial infections
T2 - a nested case-control study
AU - Rottier, Wouter C
AU - van Werkhoven, Cornelis H
AU - Bamberg, Yara R P
AU - Dorigo-Zetsma, J Wendelien
AU - van de Garde, Ewoudt M
AU - van Hees, Babette C
AU - Kluytmans, Jan A J W
AU - Kuck, Emile M
AU - van der Linden, Paul D
AU - Prins, Jan M
AU - Thijsen, Steven F T
AU - Verbon, Annelies
AU - Vlaminckx, Bart J M
AU - Ammerlaan, Heidi S M
AU - Bonten, Marc J M
N1 - Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
PY - 2018/12
Y1 - 2018/12
N2 - Objectives: Current guidelines for the empirical antibiotic treatment predict the presence of third-generation cephalosporin-resistant enterobacterial bacteraemia (3GCR-E-Bac) in case of infection only poorly, thereby increasing unnecessary carbapenem use. We aimed to develop diagnostic scoring systems which can better predict the presence of 3GCR-E-Bac. Methods: A retrospective nested case–control study was performed that included patients ≥18 years of age from eight Dutch hospitals in whom blood cultures were obtained and intravenous antibiotics were initiated. Each patient with 3GCR-E-Bac was matched to four control infection episodes within the same hospital, based on blood-culture date and onset location (community or hospital). Starting from 32 commonly described clinical risk factors at infection onset, selection strategies were used to derive scoring systems for the probability of community- and hospital-onset 3GCR-E-Bac. Results: 3GCR-E-Bac occurred in 90 of 22 506 (0.4%) community-onset infections and in 82 of 8110 (1.0%) hospital-onset infections, and these cases were matched to 360 community-onset and 328 hospital-onset control episodes. The derived community-onset and hospital-onset scoring systems consisted of six and nine predictors, respectively. With selected score cut-offs, the models identified 3GCR-E-Bac with sensitivity equal to existing guidelines (community-onset: 54.3%; hospital-onset: 81.5%). However, they reduced the proportion of patients classified as at risk for 3GCR-E-Bac (i.e. eligible for empirical carbapenem therapy) with 40% (95%CI 21–56%) and 49% (95%CI 39–58%) in, respectively, community-onset and hospital-onset infections. Conclusions: These prediction scores for 3GCR-E-Bac, specifically geared towards the initiation of empirical antibiotic treatment, may improve the balance between inappropriate antibiotics and carbapenem overuse.
AB - Objectives: Current guidelines for the empirical antibiotic treatment predict the presence of third-generation cephalosporin-resistant enterobacterial bacteraemia (3GCR-E-Bac) in case of infection only poorly, thereby increasing unnecessary carbapenem use. We aimed to develop diagnostic scoring systems which can better predict the presence of 3GCR-E-Bac. Methods: A retrospective nested case–control study was performed that included patients ≥18 years of age from eight Dutch hospitals in whom blood cultures were obtained and intravenous antibiotics were initiated. Each patient with 3GCR-E-Bac was matched to four control infection episodes within the same hospital, based on blood-culture date and onset location (community or hospital). Starting from 32 commonly described clinical risk factors at infection onset, selection strategies were used to derive scoring systems for the probability of community- and hospital-onset 3GCR-E-Bac. Results: 3GCR-E-Bac occurred in 90 of 22 506 (0.4%) community-onset infections and in 82 of 8110 (1.0%) hospital-onset infections, and these cases were matched to 360 community-onset and 328 hospital-onset control episodes. The derived community-onset and hospital-onset scoring systems consisted of six and nine predictors, respectively. With selected score cut-offs, the models identified 3GCR-E-Bac with sensitivity equal to existing guidelines (community-onset: 54.3%; hospital-onset: 81.5%). However, they reduced the proportion of patients classified as at risk for 3GCR-E-Bac (i.e. eligible for empirical carbapenem therapy) with 40% (95%CI 21–56%) and 49% (95%CI 39–58%) in, respectively, community-onset and hospital-onset infections. Conclusions: These prediction scores for 3GCR-E-Bac, specifically geared towards the initiation of empirical antibiotic treatment, may improve the balance between inappropriate antibiotics and carbapenem overuse.
KW - Journal Article
KW - Extended-spectrum β-lactamases
KW - Clinical prediction models
KW - Empirical antibiotic therapy
KW - Enterobacteria
KW - Scoring systems
KW - Risk factors
KW - Cross Infection/blood
KW - Enterobacteriaceae/drug effects
KW - Humans
KW - Middle Aged
KW - Risk Factors
KW - Male
KW - Case-Control Studies
KW - Bacteremia/diagnosis
KW - Microbial Sensitivity Tests
KW - Cephalosporins/adverse effects
KW - Female
KW - Aged
KW - Retrospective Studies
KW - Anti-Bacterial Agents/adverse effects
KW - Enterobacteriaceae Infections/blood
KW - Extended-spectrum beta-lactamases
UR - http://www.scopus.com/inward/record.url?scp=85047325455&partnerID=8YFLogxK
U2 - 10.1016/j.cmi.2018.03.023
DO - 10.1016/j.cmi.2018.03.023
M3 - Article
C2 - 29581056
SN - 1198-743X
VL - 24
SP - 1315
EP - 1321
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 12
ER -